AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PHILADELPHIA -- When used in pharmacologic doses, interferon-[alpha] is not associated with a higher incidence of fetal malformations or adverse pregnancy outcomes, according to a review of 35 case reports presented at the annual meeting of the American College of Obstetricians and Gynecologists.
Interferon-[alpha] (IFN-[alpha]) carries a category C designation, which means its safety in pregnancy has not been established.
"[IFN-[alpha]] has been effective in reducing hepatitis C RNA in the nonpregnant adult population. However, its safety in pregnancy has been questioned, and it has never been studied in a clinical trial," Dr. Jacquelyn Jai Pelham said.
"To shed some light on the subject, I combined case reports and reported the overall pregnancy outcomes ... using all the published information we have on pregnancy outcome and interferon use," said Dr. Pelham of Jefferson Medical College, Philadelphia.
She searched Medline and found 35 pregnancies with 36 fetuses exposed to IFN-[alpha]. The mean maternal age was 30 years. Treatment indications were essential thrombocythemia (46%), chronic myelogenous leukemia (29%), hepatitis C (11%), hairy cell leukemia (6%), Hodgkin's lymphoma (3%), multiple myeloma (3%), and chronic demyelinating polyneuropathy (3%).
The average weekly dose among the 35 pregnancies was 14.7 million U, ...
Source: HighBeam Research, Review of 35 pregnancies: IFN-[alpha] data indicate no increased...